Wall Street analysts say Pfizer and Moderna could make $32 billion revenue by selling the Covid-19 vaccine in 2021 alone. US news media CNN reported this information.
Many countries are approving the Covid-19 vaccine on an emergency basis. Analysts say it is a milestone for science, economics and humanity. This will not hurt the business of vaccine producers.
According to Morgan Stanley, Pfizer will make $19 billion in 2021 by selling the Covid-19 vaccine. In addition, this year there is $975 million for this vaccine.
Pfizer is producing the Covid-19 vaccine jointly with BioNTech. As a result, a portion of the revenue they will earn from selling vaccines will have to be shared with BioNTech.
Recently, advisers to the US Food and Drug Administration (FDA) said the vaccine would be introduced in the United States soon. And earlier this month, the Pfizer vaccine was introduced in the UK.
However, not only in 2021, vaccination will continue in 2022 and even in 2023. Pfizer will earn also $9.3 billion in revenue in the next two years.
Pfizer and Modern are not one. Pfizer is one of the largest pharmaceutical companies in the world. According to the Covid-19 vaccine share market value, their share price has risen 12 percent this year. And Wall Street’s S&P 500 index has risen 13.5 percent this year.
Poibarro has become modern. Where they used to be an anonymous company, they are now a $62 billion company. Modern shares have risen 70 percent this year. According to Morgan Stanley, half of Modern’s assessments are due to vaccines.
According to Goldman Sachs, Moderna will generate $13.2 billion in revenue in 2021. Of course, the estimates of others are higher.
On the other hand, Morgan Stanley says the way modern stock prices are rising, they will generate $10 to $15 billion in revenue in 2021 and 2022.